GEN Exclusives

More »

Insight & Intelligence™

Back to Item »

Genentech Goes Beyond Antibodies with Bayhill Therapeutics Diabetes Deal

Limitations with using mAbs for chronic diseases, and negative results from line-extension trials with Avastin are possible reasons.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »